All nine members of the committee unanimously voted to recommend Moderna's new mRNA influenza vaccine for adults 50 and over.

Older adults who face the highest rates of flu hospitalization moved one step closer to a new vaccine option on June 18, 2026 ...

The panel unanimously said that the benefits of Moderna's mRNA jab outweigh its risks in preventing influenza in certain age ...

Your resource for the hottest moving stocks and news. We cover all sectors and markets giving everyday investors access to ...

When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.

After canceling a routine meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to review the composition of the 2025-2026 influenza vaccine, the US Food and Drug ...

Moderna seeks FDA approval of its new shot, mFlusvia, as option for 50 and older ...

By Christy Santhosh and Mariam Sunny June 18 (Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday backed approval of Moderna's flu vaccine for adults aged 50 and older, saying its ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a ...

A new kind of flu vaccine moved a step closer to the U.S. market Thursday as federal health advisers recommended approval of ...